Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1991 Apr 15;88(8):3407–3411. doi: 10.1073/pnas.88.8.3407

Rational design of receptor-specific variants of human growth hormone.

B C Cunningham 1, J A Wells 1
PMCID: PMC51456  PMID: 2014261

Abstract

Human growth hormone (hGH) binds to both the growth hormone (GH) and the prolactin (PRL) receptors. Competition experiments followed by mutational analysis show that the epitope on hGH for hPRL receptor consists of strong determinants in the middle of helix 1 (comprising residues His-18, His-21, and Phe-25), a loop region (including Ile-58, Ser-62, and Asn-63), and the central portion of helix 4 (containing residues Arg-167, Lys-168, Lys-172, Glu-174, Phe-176, and Arg-178). When these residues are mapped on a structural model of hGH, they form a patch that overlaps but is not identical to that previously determined for the hGH receptor. Three of these side chains (His-18, His-21, and Glu-174) are ligands for binding Zn2+, which is required for high-affinity hGH-hPRL receptor complex formation. By introducing pairs of mutations into hGH that exploit the zinc dependency for hPRL receptor binding and remove side chains in the nonoverlapping regions, we have shifted the binding preference toward the hGH receptor by a factor of 34,000 or toward the hPRL receptor by a factor of 150 without substantial loss in binding affinity for the preferred receptor. The energetic effects of the individual mutations are additive within the double mutants, suggesting that each functions independently and does not introduce gross perturbations in structure. Such receptor-selective variants of hGH should be useful molecular probes to link specific receptor binding events to the various biological activities of hGH.

Full text

PDF
3407

Images in this article

3410Image
on p.3410
3410Image
on p.3410
3410Image
on p.3410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Meguid S. S., Shieh H. S., Smith W. W., Dayringer H. E., Violand B. N., Bentle L. A. Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci U S A. 1987 Sep;84(18):6434–6437. doi: 10.1073/pnas.84.18.6434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barnard R., Bundesen P. G., Rylatt D. B., Waters M. J. Monoclonal antibodies to the rabbit liver growth hormone receptor: production and characterization. Endocrinology. 1984 Nov;115(5):1805–1813. doi: 10.1210/endo-115-5-1805. [DOI] [PubMed] [Google Scholar]
  3. Binder L., Gertler A., Elberg G., Guy R., Vogel T. Site-directed mutations of human growth hormone that selectively modify its lactogenic activity and binding properties. Mol Endocrinol. 1990 Jul;4(7):1060–1068. doi: 10.1210/mend-4-7-1060. [DOI] [PubMed] [Google Scholar]
  4. Boutin J. M., Edery M., Shirota M., Jolicoeur C., Lesueur L., Ali S., Gould D., Djiane J., Kelly P. A. Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol Endocrinol. 1989 Sep;3(9):1455–1461. doi: 10.1210/mend-3-9-1455. [DOI] [PubMed] [Google Scholar]
  5. Cascieri M. A., Chicchi G. G., Applebaum J., Green B. G., Hayes N. S., Bayne M. L. Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors. J Biol Chem. 1989 Feb 5;264(4):2199–2202. [PubMed] [Google Scholar]
  6. Chang C. N., Rey M., Bochner B., Heyneker H., Gray G. High-level secretion of human growth hormone by Escherichia coli. Gene. 1987;55(2-3):189–196. doi: 10.1016/0378-1119(87)90279-4. [DOI] [PubMed] [Google Scholar]
  7. Chang M. S., Lowe D. G., Lewis M., Hellmiss R., Chen E., Goeddel D. V. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature. 1989 Sep 7;341(6237):68–72. doi: 10.1038/341068a0. [DOI] [PubMed] [Google Scholar]
  8. Chawla R. K., Parks J. S., Rudman D. Structural variants of human growth hormone: biochemical, genetic, and clinical aspects. Annu Rev Med. 1983;34:519–547. doi: 10.1146/annurev.me.34.020183.002511. [DOI] [PubMed] [Google Scholar]
  9. Cunningham B. C., Bass S., Fuh G., Wells J. A. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990 Dec 21;250(4988):1709–1712. doi: 10.1126/science.2270485. [DOI] [PubMed] [Google Scholar]
  10. Cunningham B. C., Henner D. J., Wells J. A. Engineering human prolactin to bind to the human growth hormone receptor. Science. 1990 Mar 23;247(4949 Pt 1):1461–1465. doi: 10.1126/science.247.4949.1461. [DOI] [PubMed] [Google Scholar]
  11. Cunningham B. C., Jhurani P., Ng P., Wells J. A. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science. 1989 Mar 10;243(4896):1330–1336. doi: 10.1126/science.2466339. [DOI] [PubMed] [Google Scholar]
  12. Cunningham B. C., Wells J. A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 1989 Jun 2;244(4908):1081–1085. doi: 10.1126/science.2471267. [DOI] [PubMed] [Google Scholar]
  13. Edwards C. K., 3rd, Ghiasuddin S. M., Schepper J. M., Yunger L. M., Kelley K. W. A newly defined property of somatotropin: priming of macrophages for production of superoxide anion. Science. 1988 Feb 12;239(4841 Pt 1):769–771. doi: 10.1126/science.2829357. [DOI] [PubMed] [Google Scholar]
  14. Freemark M., Comer M., Korner G., Handwerger S. A unique placental lactogen receptor: implications for fetal growth. Endocrinology. 1987 May;120(5):1865–1872. doi: 10.1210/endo-120-5-1865. [DOI] [PubMed] [Google Scholar]
  15. Fuh G., Mulkerrin M. G., Bass S., McFarland N., Brochier M., Bourell J. H., Light D. R., Wells J. A. The human growth hormone receptor. Secretion from Escherichia coli and disulfide bonding pattern of the extracellular binding domain. J Biol Chem. 1990 Feb 25;265(6):3111–3115. [PubMed] [Google Scholar]
  16. Hughes J. P., Friesen H. G. The nature and regulation of the receptors for pituitary growth hormone. Annu Rev Physiol. 1985;47:469–482. doi: 10.1146/annurev.ph.47.030185.002345. [DOI] [PubMed] [Google Scholar]
  17. Isaksson O. G., Edén S., Jansson J. O. Mode of action of pituitary growth hormone on target cells. Annu Rev Physiol. 1985;47:483–499. doi: 10.1146/annurev.ph.47.030185.002411. [DOI] [PubMed] [Google Scholar]
  18. Lefkowitz R. J., Caron M. G. Adrenergic receptors. Models for the study of receptors coupled to guanine nucleotide regulatory proteins. J Biol Chem. 1988 Apr 15;263(11):4993–4996. [PubMed] [Google Scholar]
  19. Lefkowitz R. J., Stadel J. M., Caron M. G. Adenylate cyclase-coupled beta-adrenergic receptors: structure and mechanisms of activation and desensitization. Annu Rev Biochem. 1983;52:159–186. doi: 10.1146/annurev.bi.52.070183.001111. [DOI] [PubMed] [Google Scholar]
  20. Leung D. W., Spencer S. A., Cachianes G., Hammonds R. G., Collins C., Henzel W. J., Barnard R., Waters M. J., Wood W. I. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature. 1987 Dec 10;330(6148):537–543. doi: 10.1038/330537a0. [DOI] [PubMed] [Google Scholar]
  21. Robb R. J., Greene W. C., Rusk C. M. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med. 1984 Oct 1;160(4):1126–1146. doi: 10.1084/jem.160.4.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Robb R. J., Rusk C. M., Neeper M. P. Structure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysis. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5654–5658. doi: 10.1073/pnas.85.15.5654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roguin L. P., Cohen C. E., Retegui L. A. Monoclonal antibodies as probes to study the human growth hormone-binding domain to lactogenic rat liver receptors. Endocrinology. 1990 Sep;127(3):1009–1015. doi: 10.1210/endo-127-3-1009. [DOI] [PubMed] [Google Scholar]
  24. Vonderhaar B. K., Ziska S. E. Hormonal regulation of milk protein gene expression. Annu Rev Physiol. 1989;51:641–652. doi: 10.1146/annurev.ph.51.030189.003233. [DOI] [PubMed] [Google Scholar]
  25. Wells J. A. Additivity of mutational effects in proteins. Biochemistry. 1990 Sep 18;29(37):8509–8517. doi: 10.1021/bi00489a001. [DOI] [PubMed] [Google Scholar]
  26. Zoller M. J., Smith M. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acids Res. 1982 Oct 25;10(20):6487–6500. doi: 10.1093/nar/10.20.6487. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES